Aquestive Therapeutics, Inc.

AQST

US03843E1047

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
3.11 ^USD	-5.18%		+0.65%	+53.96%

05-10	Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target	MT
05-08	Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024

Aquestive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 07, 2024 at 04:24 pm

Aquestive Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 12.05 million compared to USD 11.13 million a year ago. Net loss was USD 12.83 million compared to net income of USD 8.07 million a year ago.

Latest news about Aquestive Therapeutics, Inc.

Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target	05-10	MT
Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
Earnings Flash (AQST) AQUESTIVE THERAPEUTICS Posts Q1 Revenue $12.1M, vs. Street Est of $12.3M	05-07	MT
Aquestive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Aquestive Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024	05-07	CI
Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children	04-29	MT
Transcript : Aquestive Therapeutics, Inc. - Special Call	04-29
Aquestive Therapeutics, Inc Receives U.S. FDA Approval and Market Access for Libervant? Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm? (epinephrine) Sublingual Film	04-29	CI
Aquestive Therapeutics, Inc. to Present Crossover Study Data for Libervant Buccal Film At 76th Annual Meeting of the American Academy of Neurology	04-12	CI
Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target	04-11	MT
Aquestive Therapeutics Files $250 Million Mixed Shelf	04-03	MT
Aquestive Therapeutics, Inc. Appoints Abigail Jenkins to Board of Directors, Effective April 1, 2024	04-01	CI
Raymond James Initiates Aquestive Therapeutics With Outperform Rating, $7 Price Target	03-28	MT
Top Midday Decliners	03-20	MT
Sector Update: Health Care Stocks Steady Premarket Wednesday	03-20	MT
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply	03-20	MT
Top Premarket Decliners	03-20	MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering; Shares Slump Premarket	03-20	MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering	03-20	MT
Aquestive Therapeutics Proposes Public Stock Offering -- Shares Drop	03-19	MT
H.C. Wainwright Raises Price Target on Aquestive Therapeutics to $9 From $7, Maintains Buy Rating	03-18	MT
JMP Securities Adjusts Price Target on Aquestive Therapeutics to $10 From $8, Maintains Market Outperform Rating	03-15	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	03-15	MT
Aquestive Therapeutics' Anaphylm Demonstrates Faster Maximum Concentration Reach in Phase 3 Trial	03-14	MT
Aquestive Therapeutics, Inc. Releases Positive Topline Clinical Data from Its Phase 3 Pivotal Pharmacokinetic (PK) Clinical Study of Anaphylm (Epinephrine) Sublingual Film and Findings from the FDA Type C meeting	03-14	CI

Chart Aquestive Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Companyâs Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.

Sector

Pharmaceuticals

Calendar

2024-06-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Aquestive Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.11 USD

Average target price

8.611 USD

Spread / Average Target

+176.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AQUESTIVE THERAPEUTICS, INC.	+53.96%	283M
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals